Circulating plasma microRNA-126, microRNA-145, and microRNA-155 and their association with atherosclerotic plaque characteristics
Background and Aim: Circulating microRNAs (miRNAs) have been identified as biomarkers for several diseases. Dysregulation of miRNA-126, -145 and -155 have been shown to be associated with atherosclerotic lesion formation. The aim of this study was to evaluate the association between atherosclerosis-related miRNAs and unfavourable atherosclerotic plaque characteristics.
Methods and Results: Forty patients with stable coronary artery disease (CAD) admitted for elective percutaneous coronary intervention (PCI) were enrolled in a prospective study. After PCI, intravascular ultrasound (IVUS) and iMAP-IVUS analysis was performed to assess the proportion of fibrotic, necrotic, lipidic and calcific tissue within atherosclerotic plaques. Total RNA was isolated from plasma to evaluate the expression of circulating miRNA-126, miRNA-145 and miRNA-155. Plasma lipid and glucose metabolism-related variables were measured to determine any association with plaque characteristics or miRNA expression. Expression of miRNA-126 was negatively correlated with plaque fibrotic tissue (r=-0.28; p=0.044), while positively correlated with plaque necrotic tissue (r=0.31; p=0.029) and necrolipidic tissue (r=0.31; p=0.031). MiRNA-145 was positively correlated with plaque lipidic (r=0.32; p=0.023) and necrolipidic tissue (r=0.31; p=0.029). Patient age was associated with plaque fibrotic tissue (r=-0.41; p=0.005), necrotic tissue (r=0.33; p=0.022), and lipid content (r=0.33; p=0.022). HDL-C was positively correlated with plaque necrotic (r=0.28; p=0.042) and calcific (r=0.28; p=0.044) tissue volume. Calcific tissue volume was positively correlated with C-peptide (r=0.34; p=0.033). After multivariate logistic regression analysis, both miRNA-126 and miRNA-145 expression were associated with increased necrolipidic tissue content (β=0.34; p=0.050; and β=0.35; p=0.037 respectively).
Conclusions: Expression of miRNA-126 and miRNA-145 were associated with increased plaque necrolipidic tissue content.
Relevance for patients: Although further research is needed to support the study data, miRNA-126 and miRNA-145 may serve as potential plaque vulnerability biomarkers in the future.
[1] Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V, Bansal P. MicroRNA Therapeutics: Discovering Novel Targets and Developing Specific Therapy. Perspect Clin Res 2016;7:68-74.
[2] Qu QQ, MJ MM, PanJJ, Shi XJ, Zhang ZJ, TangYH, Yang GY. MicraRNA-126 is a Prospective Target for Vascular Disease. Neuroimmunol Neuroinflammation 2018:5-10.
[3] Raitoharju E, Oksala N, Lehtimaki T. MicroRNAs in the Atherosclerotic Plaque. Clin Chem 2013;12:1708-21.
[4] Andreou I, Sun X, Stone PH, Edelman ER, Feinberg MW. miRNAs in Atherosclerotic Plaque Initiation, Progression, and Rupture. Trends Mol Med 2015;21:307-18.
[5] Zhao W, Zhao SP, Zhao YH. MicroRNA-143/-145 in Cardiovascular Diseases. Biomed Res Int 2015;2015:531740.
[6] Cao RY, Li Q, Miao Y, Zhang Y, Yuan W, Fan L, et al. The Emerging Role of MicroRNA-155 in Cardiovascular Diseases. Biomed Res Int 2016;2016:9869208.
[7] Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR, et al. MicroRNA-155 Promotes Atherosclerosis by Repressing Bcl6 in Macrophages. J Clin Invest 2012;122:4190-202.
[8] Du F, Yu F, Wang Y, Hui Y, Carnevale K, Fu M, et al. MicroRNA-155 Deficiency Results in Decreased Macrophage Inflammation and Attenuated Atherogenesis in Apolipoprotein E-Deficient Mice. Arterioscler Thromb Vasc Biol 2014;34:759-67.
[9] Zhu J, Chen T, Yang L, Li Z, Wong MM, Zheng X, et al. Regulation of microRNA-155 in Atherosclerotic Inflammatory Responses by Targeting MAP3K10. PLoS One 2012;7:e46551.
[10] Donners MM, Wolfs IM, Stöger LJ, van der Vorst EP, Pöttgens CC, Heymans S, et al. Hematopoietic miR155 Deficiency Enhances Atherosclerosis and Decreases Plaque Stability in Hyperlipidemic Mice. PLoS One 2012;7:e35877.
[11] Sathyanarayana S, Carlier S, Li W, Thomas L. Characterisation of Atherosclerotic Plaque by Spectral Similarity of Radiofrequency Intravascular Ultrasound Signals. EuroIntervention 2009;5:133-9.
[12] Shin ES, Garcia-Garcia HM, Ligthart JM, Witberg K, Schultz C, van der Steen AF, et al. In vivo Findings of Tissue Characteristics Using iMap™ IVUS and Virtual Histology™ IVUS. EuroIntervention 2011;6:1017-9.
[13] American DiabetesAssociation. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010;33 Suppl 1:S62-9.
[14] Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al.American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. JAm Coll Cardiol 2001;37:1478-92.
[15] Ren J, Zhang J, Xu N, Han G, Geng Q, Song J, et al. Signature of Circulating microRNAs as Potential Biomarkers in Vulnerable Coronary Artery Disease. PLoS One 2013;8:e80738.
[16] Leistner DM, Boeckel JN, Reis SM, Thome CE, De Rosa R, Keller T, et al. Transcoronary Gradients of Vascular miRNAs and Coronary Atherosclerotic Plaque Characteristics. Eur Heart J 2016;37:1738-49.
[17] Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating microRNAs in Patients with Coronary Artery Disease. Circ Res 2010;107:677-84.
[18] Li HY, Zhao X, Liu YZ, Meng Z, Wang D, Yang F, et al. Plasma microRNA-126-5p is Associated with the Complexity and Severity of Coronary Artery Disease in Patients with Stable Angina Pectoris. Cell Physiol Biochem 2016;39:837-46.
[19] Faccini J, Ruidavets JB, Cordelier P, Martins F, Maoret JJ, Bongard V, et al. Circulating miR-155,miR-145 and let-7c as Diagnostic Biomarkers of the Coronary Artery Disease. Sci Rep 2017;7:42916.
[20] Gao H, GuddetiRR, MatsuzawaY, Liu LP, Su LX, Guo D, et al. Plasma Levels of microRNA-145 are Associated with Severity of Coronary Artery Disease. PLoS One 2015;10:e0123477.
[21] Lin X, Qin Y, Jia J, Lin T, Lin X, Chen L, et al. MiR-155 Enhances Insulin Sensitivity by Coordinated Regulation of Multiple Genes in Mice. PLoS Genet 2016;12:e1006308.
[22] Zhu M,Wei Y, Geißler C,Abschlag K, Corbalán Campos J, HristovM, et al. Hyperlipidemia-induced microRNA-155- 5p Improves β-cell Function by Targeting Mafb. Diabetes 2017;66:3072-84.
[23] Sun B, Zhao H, Liu X, Lu Q, Zhao X, Pu J, et al. Elevated Hemoglobin A1c is Associated with Carotid Plaque Vulnerability: Novel Findings from Magnetic Resonance Imaging Study in Hypertensive Stroke Patients. Sci Rep 2016;6:33246.
[24] Kim SH, Moon JY, LimYM, Kim KH, Yang WI, Sung JH, et al. Association of Insulin Resistance and Coronary Artery Remodeling: An Intravascular Ultrasound Study. Cardiovasc Diabetol 2015;14:74.
[25] Iguchi T, Hasegawa T, Otsuka K, Matsumoto K, Yamazaki T, Nishimura S, et al. Insulin Resistance is Associated with Coronary Plaque Vulnerability: Insight from Optical Coherence Tomography Analysis. Eur Heart J Cardiovasc Imaging 2014;15:284-91.
[26] Mitsuhashi T, Hibi K, Kosuge M, Morita S, Komura N, Kusama I, et al. Relation between Hyperinsulinemia and Nonculprit Plaque Characteristics in Nondiabetic Patients with Acute Coronary Syndromes. JACC Cardiovasc Imaging 2011;4:392-401.
[27] Amano T, Matsubara T, Uetani T, Nanki M, Marui N, Kato M, et al. Abnormal Glucose Regulation is Associated with Lipid-rich Coronary Plaque: Relationship to Insulin Resistance. JACC Cardiovasc Imaging 2008;1:39-45.